JP2015500286A - ナトリウムイオンおよびカルシウムイオンの医薬組成物ならびにがん、腫瘍、および非悪性腫瘍を治療する方法 - Google Patents
ナトリウムイオンおよびカルシウムイオンの医薬組成物ならびにがん、腫瘍、および非悪性腫瘍を治療する方法 Download PDFInfo
- Publication number
- JP2015500286A JP2015500286A JP2014546003A JP2014546003A JP2015500286A JP 2015500286 A JP2015500286 A JP 2015500286A JP 2014546003 A JP2014546003 A JP 2014546003A JP 2014546003 A JP2014546003 A JP 2014546003A JP 2015500286 A JP2015500286 A JP 2015500286A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- medicinal ion
- treatment
- ion bomb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 491
- 201000011510 cancer Diseases 0.000 title claims abstract description 267
- 238000000034 method Methods 0.000 title claims abstract description 72
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 54
- 239000011734 sodium Substances 0.000 title abstract description 138
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 title abstract description 14
- 229910001424 calcium ion Inorganic materials 0.000 title abstract description 14
- 229910001415 sodium ion Inorganic materials 0.000 title abstract description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title abstract description 5
- 238000011282 treatment Methods 0.000 claims abstract description 187
- 238000002347 injection Methods 0.000 claims abstract description 143
- 239000007924 injection Substances 0.000 claims abstract description 143
- 230000002601 intratumoral effect Effects 0.000 claims abstract description 113
- 201000010099 disease Diseases 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 14
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 14
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 13
- 208000003174 Brain Neoplasms Diseases 0.000 claims abstract description 11
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 11
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims abstract description 10
- 208000000571 Fibrocystic breast disease Diseases 0.000 claims abstract description 10
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims abstract description 10
- 210000001685 thyroid gland Anatomy 0.000 claims abstract description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 107
- 239000011780 sodium chloride Substances 0.000 claims description 53
- 206010006187 Breast cancer Diseases 0.000 claims description 47
- 208000026310 Breast neoplasm Diseases 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 34
- 230000003902 lesion Effects 0.000 claims description 25
- 201000001441 melanoma Diseases 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 208000031513 cyst Diseases 0.000 claims description 15
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 14
- 230000003211 malignant effect Effects 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 206010011732 Cyst Diseases 0.000 claims description 11
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 11
- 208000007256 Nevus Diseases 0.000 claims description 10
- 208000003200 Adenoma Diseases 0.000 claims description 8
- 206010024612 Lipoma Diseases 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 210000000496 pancreas Anatomy 0.000 claims description 8
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 8
- 208000037819 metastatic cancer Diseases 0.000 claims description 7
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 201000002510 thyroid cancer Diseases 0.000 claims description 6
- 208000009453 Thyroid Nodule Diseases 0.000 claims description 5
- 201000009023 maxillary cancer Diseases 0.000 claims description 5
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010018498 Goitre Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 4
- 206010034299 Penile cancer Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 206010016629 fibroma Diseases 0.000 claims description 4
- 201000003872 goiter Diseases 0.000 claims description 4
- 201000011066 hemangioma Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 238000012285 ultrasound imaging Methods 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 3
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 201000002893 dermoid cyst of ovary Diseases 0.000 claims description 2
- 230000003176 fibrotic effect Effects 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 201000010260 leiomyoma Diseases 0.000 claims description 2
- 208000004971 ovarian teratoma Diseases 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 3
- 206010001233 Adenoma benign Diseases 0.000 claims 2
- 206010006256 Breast hyperplasia Diseases 0.000 claims 2
- 208000011803 breast fibrocystic disease Diseases 0.000 claims 2
- 230000001815 facial effect Effects 0.000 claims 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- 206010046799 Uterine leiomyosarcoma Diseases 0.000 claims 1
- 208000000260 Warts Diseases 0.000 claims 1
- 208000016842 benign thyroid gland neoplasm Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000009738 saturating Methods 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 claims 1
- 201000000195 skin tag Diseases 0.000 claims 1
- 206010043688 thyroid adenoma Diseases 0.000 claims 1
- 201000007954 uterine fibroid Diseases 0.000 claims 1
- 150000002500 ions Chemical class 0.000 abstract description 332
- 239000000243 solution Substances 0.000 abstract description 177
- 241000282414 Homo sapiens Species 0.000 abstract description 124
- 210000004185 liver Anatomy 0.000 abstract description 13
- 238000009093 first-line therapy Methods 0.000 abstract description 12
- 210000000056 organ Anatomy 0.000 abstract description 8
- 210000000481 breast Anatomy 0.000 abstract description 7
- 210000004392 genitalia Anatomy 0.000 abstract description 7
- 210000004072 lung Anatomy 0.000 abstract description 7
- 229920006395 saturated elastomer Polymers 0.000 abstract description 7
- 206010033675 panniculitis Diseases 0.000 abstract description 6
- 238000007920 subcutaneous administration Methods 0.000 abstract description 6
- 210000004304 subcutaneous tissue Anatomy 0.000 abstract description 6
- 210000004556 brain Anatomy 0.000 abstract description 5
- 210000002307 prostate Anatomy 0.000 abstract description 5
- 206010004412 Benign neoplasm of thyroid gland Diseases 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 167
- 239000011575 calcium Substances 0.000 description 127
- 241000699666 Mus <mouse, genus> Species 0.000 description 47
- 210000001519 tissue Anatomy 0.000 description 47
- 241001465754 Metazoa Species 0.000 description 37
- 210000000170 cell membrane Anatomy 0.000 description 33
- 238000011580 nude mouse model Methods 0.000 description 31
- 241000699660 Mus musculus Species 0.000 description 29
- 210000003722 extracellular fluid Anatomy 0.000 description 29
- 210000002977 intracellular fluid Anatomy 0.000 description 28
- 238000001356 surgical procedure Methods 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 25
- 230000002147 killing effect Effects 0.000 description 24
- 239000008280 blood Substances 0.000 description 22
- 230000001575 pathological effect Effects 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 21
- 210000004204 blood vessel Anatomy 0.000 description 19
- 230000006378 damage Effects 0.000 description 19
- 230000034994 death Effects 0.000 description 17
- 231100000517 death Toxicity 0.000 description 17
- 238000009792 diffusion process Methods 0.000 description 17
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- 206010028851 Necrosis Diseases 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 238000010255 intramuscular injection Methods 0.000 description 15
- 239000007927 intramuscular injection Substances 0.000 description 15
- 230000017074 necrotic cell death Effects 0.000 description 15
- 238000002203 pretreatment Methods 0.000 description 15
- 210000004413 cardiac myocyte Anatomy 0.000 description 14
- 239000012528 membrane Substances 0.000 description 14
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 13
- 238000002591 computed tomography Methods 0.000 description 13
- 230000004941 influx Effects 0.000 description 12
- 206010039491 Sarcoma Diseases 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 235000013601 eggs Nutrition 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 241000272525 Anas platyrhynchos Species 0.000 description 9
- 206010060862 Prostate cancer Diseases 0.000 description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- 201000009030 Carcinoma Diseases 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 8
- 208000014018 liver neoplasm Diseases 0.000 description 8
- 238000010561 standard procedure Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 230000002588 toxic effect Effects 0.000 description 8
- 210000000264 venule Anatomy 0.000 description 8
- 210000002565 arteriole Anatomy 0.000 description 7
- 230000036978 cell physiology Effects 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 230000003908 liver function Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000001338 necrotic effect Effects 0.000 description 7
- 210000004940 nucleus Anatomy 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 230000001112 coagulating effect Effects 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 231100000682 maximum tolerated dose Toxicity 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 102000004310 Ion Channels Human genes 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000003204 osmotic effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000012453 sprague-dawley rat model Methods 0.000 description 5
- 231100000027 toxicology Toxicity 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 208000037273 Pathologic Processes Diseases 0.000 description 4
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000000642 iatrogenic effect Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000003463 organelle Anatomy 0.000 description 4
- 230000004203 pancreatic function Effects 0.000 description 4
- 230000009054 pathological process Effects 0.000 description 4
- 210000003899 penis Anatomy 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 231100000160 chronic toxicity Toxicity 0.000 description 3
- 230000007665 chronic toxicity Effects 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 235000013345 egg yolk Nutrition 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004199 lung function Effects 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 238000009607 mammography Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 239000003104 tissue culture media Substances 0.000 description 3
- 206010000591 Acrochordon Diseases 0.000 description 2
- 206010060999 Benign neoplasm Diseases 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100038083 Endosialin Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100027988 GTP-binding protein Rhes Human genes 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010073069 Hepatic cancer Diseases 0.000 description 2
- 101000684297 Homo sapiens 26S proteasome complex subunit SEM1 Proteins 0.000 description 2
- 101000884275 Homo sapiens Endosialin Proteins 0.000 description 2
- 101000578396 Homo sapiens GTP-binding protein Rhes Proteins 0.000 description 2
- 101001096065 Homo sapiens Plexin domain-containing protein 1 Proteins 0.000 description 2
- 101000873438 Homo sapiens Putative protein SEM1, isoform 2 Proteins 0.000 description 2
- 101000650808 Homo sapiens Semaphorin-3G Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102100037891 Plexin domain-containing protein 1 Human genes 0.000 description 2
- 102100034920 Putative protein SEM1, isoform 2 Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000037323 Rare tumor Diseases 0.000 description 2
- 102100027750 Semaphorin-3G Human genes 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000004611 cancer cell death Effects 0.000 description 2
- 230000003327 cancerostatic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 210000002767 hepatic artery Anatomy 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 201000002250 liver carcinoma Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000009525 mild injury Effects 0.000 description 2
- 238000002324 minimally invasive surgery Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 238000002638 palliative care Methods 0.000 description 2
- 230000001936 parietal effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000036514 plasma sodium concentration Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010051093 Cardiopulmonary failure Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000235503 Glomus Species 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010062062 Large intestinal obstruction Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 231100000229 OECD 452 Chronic Toxicity Study Toxicity 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 201000003163 breast adenoma Diseases 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 208000030377 glomuvenous malformation Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 208000011824 leiomyosarcoma of the corpus uteri Diseases 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 208000019303 maxillary sinus carcinoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000013169 thromboelastometry Methods 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566655P | 2011-12-04 | 2011-12-04 | |
| US61/566,655 | 2011-12-04 | ||
| PCT/US2012/067802 WO2013133873A2 (en) | 2011-12-04 | 2012-12-04 | Pharmaceutical compositions of sodium ion and calcium ion and methods for treating cancer, tumor and non-malignancy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016234317A Division JP6659525B2 (ja) | 2011-12-04 | 2016-12-01 | がん、腫瘍、および非悪性疾患を治療するためのナトリウムイオンおよびカルシウムイオンの医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015500286A true JP2015500286A (ja) | 2015-01-05 |
| JP2015500286A5 JP2015500286A5 (https=) | 2016-01-28 |
Family
ID=49117478
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546003A Pending JP2015500286A (ja) | 2011-12-04 | 2012-12-04 | ナトリウムイオンおよびカルシウムイオンの医薬組成物ならびにがん、腫瘍、および非悪性腫瘍を治療する方法 |
| JP2016234317A Expired - Fee Related JP6659525B2 (ja) | 2011-12-04 | 2016-12-01 | がん、腫瘍、および非悪性疾患を治療するためのナトリウムイオンおよびカルシウムイオンの医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016234317A Expired - Fee Related JP6659525B2 (ja) | 2011-12-04 | 2016-12-01 | がん、腫瘍、および非悪性疾患を治療するためのナトリウムイオンおよびカルシウムイオンの医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9962403B2 (https=) |
| EP (1) | EP2785357A4 (https=) |
| JP (2) | JP2015500286A (https=) |
| CN (1) | CN104244959B (https=) |
| BR (1) | BR112014013561B1 (https=) |
| IN (1) | IN2014KN01391A (https=) |
| MX (1) | MX365308B (https=) |
| RU (1) | RU2600166C2 (https=) |
| WO (1) | WO2013133873A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101683635B1 (ko) | 2014-12-29 | 2016-12-09 | 가천대학교 산학협력단 | 락테이트 금속염을 포함하는 암 치료용 약학 조성물 |
| CN113433307A (zh) * | 2020-02-10 | 2021-09-24 | 安派科生物医学科技有限公司 | 用于疾病检测和治疗的新型仪器和方法 |
| CN113181209A (zh) * | 2021-04-28 | 2021-07-30 | 黄永茂 | 调理人体经络生物电的适度氯化氢组分及其应用 |
| BE1030834B1 (fr) * | 2024-01-13 | 2025-01-07 | Yongmao Huang | Une méthode diététique pour réguler le bioélectricité des méridiens avec une solution composée de chlorure d'hydrogène pour le diabète et l'hyperlipidémie |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224349A (en) * | 1978-11-17 | 1980-09-23 | Gooch Robert C | Meat tenderizing method |
| PL188137B1 (pl) * | 1995-02-03 | 2004-12-31 | Aeterna Lab Inc | Zastosowanie wyciągu z chrząstki rekina |
| US6734018B2 (en) * | 1999-06-07 | 2004-05-11 | Lifenet | Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced |
| CN1159016C (zh) * | 2001-07-02 | 2004-07-28 | 卜子英 | 一种注射用治疗实体性肿瘤的药物组合物 |
| CN101209344B (zh) * | 2006-12-28 | 2012-07-04 | 赵超英 | 高渗液组合物在制备促进伤口愈合的药物中的应用 |
-
2012
- 2012-12-04 BR BR112014013561-4A patent/BR112014013561B1/pt not_active IP Right Cessation
- 2012-12-04 EP EP12870727.0A patent/EP2785357A4/en not_active Withdrawn
- 2012-12-04 WO PCT/US2012/067802 patent/WO2013133873A2/en not_active Ceased
- 2012-12-04 CN CN201280069015.2A patent/CN104244959B/zh not_active Expired - Fee Related
- 2012-12-04 MX MX2014006746A patent/MX365308B/es active IP Right Grant
- 2012-12-04 RU RU2014127148/15A patent/RU2600166C2/ru active
- 2012-12-04 US US14/361,818 patent/US9962403B2/en not_active Expired - Fee Related
- 2012-12-04 JP JP2014546003A patent/JP2015500286A/ja active Pending
-
2014
- 2014-07-02 IN IN1391KON2014 patent/IN2014KN01391A/en unknown
-
2016
- 2016-12-01 JP JP2016234317A patent/JP6659525B2/ja not_active Expired - Fee Related
Non-Patent Citations (6)
| Title |
|---|
| A.J.R, vol. Vol.184, JPN6016033373, January 2005 (2005-01-01), pages 212 - 219 * |
| CANCER RESEARCH, vol. Vol.39, JPN6016033374, September 1979 (1979-09-01), pages 3429 - 3434 * |
| CARCINOGENESIS, vol. 13, no. 7, JPN6016033377, 1992, pages 1155 - 1158 * |
| INTERNATIONAL JOURNAL OF PHARMACOLOGY, vol. 5, no. 1, JPN6016033375, 2009, pages 13 - 21 * |
| J.DERMATOL.SURG.ONCOL., vol. Vol.20, JPN6016033372, 1994, pages 347 - 348 * |
| J.VASC.INTERV.RADIOL., vol. 13, no. 7, JPN6016033376, 2002, pages 717 - 724 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2785357A4 (en) | 2015-08-26 |
| CN104244959B (zh) | 2019-01-04 |
| JP2017061554A (ja) | 2017-03-30 |
| WO2013133873A2 (en) | 2013-09-12 |
| US20140322359A1 (en) | 2014-10-30 |
| MX2014006746A (es) | 2016-02-10 |
| US9962403B2 (en) | 2018-05-08 |
| RU2014127148A (ru) | 2016-02-10 |
| BR112014013561B1 (pt) | 2019-04-24 |
| BR112014013561A2 (pt) | 2016-09-20 |
| EP2785357A2 (en) | 2014-10-08 |
| CN104244959A (zh) | 2014-12-24 |
| RU2600166C2 (ru) | 2016-10-20 |
| MX365308B (es) | 2019-05-29 |
| IN2014KN01391A (https=) | 2015-10-23 |
| WO2013133873A3 (en) | 2014-02-20 |
| JP6659525B2 (ja) | 2020-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12303596B2 (en) | Thermo-responsive hydrogel for intratumoral administration as a treatment in solid tumor cancers | |
| Albadawi et al. | Percutaneous liquid ablation agent for tumor treatment and drug delivery | |
| JP6659525B2 (ja) | がん、腫瘍、および非悪性疾患を治療するためのナトリウムイオンおよびカルシウムイオンの医薬組成物 | |
| CN110267644B (zh) | 用于治疗腺样囊性癌的苯磺酰胺衍生物的医药组合物 | |
| Nakao et al. | Evaluation of the morphological changes of gastric mucosa induced by a low concentration of acetic acid using a rat model | |
| CN116209432A (zh) | 组织消融方法和材料 | |
| Dai et al. | EndoClot® SIS polysaccharide injection as a submucosal fluid cushion for endoscopic mucosal therapies: results of ex vivo and in vivo studies | |
| Liu et al. | Functional paclitaxel-manganese-doped mesoporous silica nanoparticles for orthotopic brain glioma targeted therapy | |
| Qiu et al. | Res@ ZIF-90 suppress gastric cancer progression by disturbing mitochondrial homeostasis | |
| Wu et al. | Celecoxib and cisplatin dual-loaded microspheres synergistically enhance transarterial chemoembolization effect of hepatocellular carcinoma | |
| Lan et al. | Near-infrared-responsive GE11-CuS@ Gal nanoparticles as an intelligent drug release system for targeting therapy against oral squamous cell carcinoma | |
| McKaig et al. | Ultrasound targeted microbubble destruction using docetaxel and Rose Bengal loaded Microbubbles for targeted Chemo-Sonodynamic therapy treatment of prostate cancer | |
| JP2019501161A (ja) | 膀胱癌に対する光線力学的療法（ｐｄｔ）の方法 | |
| Huang et al. | Proapoptotic effect and the mechanism of action of pingyangmycin on cavernous hemangiomas | |
| Hori et al. | Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs: implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062) | |
| Shah et al. | Percutaneous Ablation of VX2 Carcinoma–induced Liver Tumors with Use of Ethanol versus Acetic Acid: Pilot Study in a Rabbit Model | |
| Wang et al. | Port-site metastasis as a primary complication following retroperitoneal laparoscopic radical resection of renal pelvis carcinoma or nephron-sparing surgery: A report of three cases and review of the literature | |
| Chen et al. | Nanosecond pulsed electric field (nsPEF) ablation as an alternative or adjunct to surgery for treatment of cancer | |
| Zhang et al. | Comparative study on the antitumor effects of gemcitabine polybutylcyanoacrylate nanoparticles coupled with anti-human MUC1 and CA199 monoclonal antibodies on pancreatic cancer in vitro and in vivo | |
| RU2743219C1 (ru) | Способ моделирования рака яичника в эксперименте у крыс | |
| Yuan et al. | Development of a Hepatic VX2 carcinoma model in rabbits using an improved minimally invasive method and evaluation with imaging examinations | |
| Fagih et al. | Scrotal necrosis following heated intra-peritoneal chemotherapy: case report and review of the literature | |
| RU2361587C1 (ru) | Лекарственное средство для лечения онкологических заболеваний | |
| Yang et al. | Injectable acid-labile thermosensitive magnetic hydrogel with responsive drug release for bridging liver transplantation in hepatocellular carcinoma | |
| RU2465924C2 (ru) | Способ лечения рака молочной железы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140811 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151202 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151202 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160906 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170328 |